Opiant Pharmaceuticals (OPNT) CFO Purchases $33,900.00 in Stock

Opiant Pharmaceuticals (NASDAQ:OPNT) CFO David D. O’toole bought 2,000 shares of the stock in a transaction dated Wednesday, May 16th. The shares were acquired at an average cost of $16.95 per share, for a total transaction of $33,900.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Opiant Pharmaceuticals traded down $0.58, hitting $16.16, during mid-day trading on Friday, according to MarketBeat.com. 19,582 shares of the company’s stock were exchanged, compared to its average volume of 21,578. The stock has a market capitalization of $43.30 million, a PE ratio of 5.50 and a beta of -0.57. Opiant Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $51.90.

Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th.

An institutional investor recently raised its position in Opiant Pharmaceuticals stock. Spark Investment Management LLC boosted its position in Opiant Pharmaceuticals (NASDAQ:OPNT) by 46.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,400 shares of the technology company’s stock after acquiring an additional 6,500 shares during the quarter. Spark Investment Management LLC owned 0.99% of Opiant Pharmaceuticals worth $468,000 at the end of the most recent reporting period. 3.71% of the stock is currently owned by institutional investors and hedge funds.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply